PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
32.68%
Some net income increase while CRVO is negative at -100.07%. John Neff would see a short-term edge over the struggling competitor.
80.19%
D&A growth well above CRVO's 45.59%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-398.37%
Negative yoy deferred tax while CRVO stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
30.65%
SBC growth while CRVO is negative at -18.24%. John Neff would see competitor possibly controlling share issuance more tightly.
27.89%
Less working capital growth vs. CRVO's 1321.58%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.29%
Negative yoy AP while CRVO is 196.03%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
66.06%
Some yoy usage while CRVO is negative at -111.03%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
30.65%
Growth of 30.65% while CRVO is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might reflect intangible expansions or partial write-offs.
-19.98%
Both yoy CFO lines are negative, with CRVO at -79.85%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-32.37%
Negative yoy CapEx while CRVO is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-271.58%
We reduce yoy invests while CRVO stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
69.11%
Debt repayment growth of 69.11% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-69.14%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.